- Location
NSCLC
"-
Survival Among People with Lung Cancer Has Been Better for Women Than Men
Mar 5, 2014Survival among people with lung cancer has been better for women than men, and the findings of a recent study indicate that female hormones may be a factor in this difference. The combination of estrogen plus progesterone and the use of ...
-
Incyte Has Entered Into a Agreement with Merck Through a Merck Subsidiary
Feb 14, 2014Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 ...
Tags: collaboration agreement, Incyte's oral indoleamine dioxygenase-1, IDO1
-
Pfizer Has Secured Regular Approval From The Us Food and Drug Administration (FDA)
Nov 25, 2013Pfizer has secured regular approval from the US Food and Drug Administration (FDA) for its Xalkori (crizotinib) capsules to treat patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). The approval was based on ...
-
Helsinn Gives Rights to Their Ghrelin Receptor Agonist to Chugai Pharma Marketing
Nov 14, 2013Switzerland-based Helsinn group has granted Chugai Pharma Marketing, a wholly-owned subsidiary of Chugai Pharmaceutical, exclusive commercialization rights to their ghrelin receptor agonist, anamorelin, for the three major European pharma ...
Tags: Helsinn group, Pharma Marketing
-
Boehringer Ingelheim Has Submitted a Marketing Authorisation Application to EMA
Oct 16, 2013Boehringer Ingelheim has submitted a marketing authorisation application to the European Medicines Agency (EMA) for the approval of its oral triple angiokinase inhibitor nintedanib. Nintedanib to be used in combination with docetaxel is ...
Tags: Boehringer Ingelheim, Lung Cancer
-
Cell Signaling Technology Has Presented a Specific HER3 Rabbit Monoclonal Antibody
Aug 30, 2013Cell Signaling Technology has presented a specific HER3 rabbit monoclonal antibody (mAb) for researchers studying HER2-mediated breast, lung and ovarian tumors. The company has introduced this product with the recent need for HER3 in HER2 ...
-
Roche Introduced New Progastrin-Releasing Peptide Test for Lung Cancer and Diagnosis SCLC
Jul 19, 2013Switzerland-based Roche has introduced new Progastrin-releasing peptide (ProGRP) test, Elecsys ProGRP, for precise differentiation of small cell (SCLC) and non-small cell (NSCLC) lung cancer and diagnosis of early-stage SCLC. Used with ...
Tags: Lung Cancer, Peptide Test
-
FDA Has Cleared Gilotrif as a New Medication for Patients with Late Stage NSCLC
Jul 16, 2013The US Food and Drug Administration (FDA) has cleared Boehringer Ingelheim's tyrosine kinase inhibitor Gilotrif (afatinib) as a new medication for patients with late stage (metastatic) non-small cell lung cancer (NSCLC). The approval also ...
Tags: FDA, Lung Cancer Therapy, Medicine
-
Genentech and Astellas Pharma US Announced That FDA Has Cleared Tarceva
May 17, 2013Roche Group member Genentech and Astellas Pharma US announced that the US Food and Drug Administration (FDA) has cleared Tarceva (erlotinib). The tablets are used for the initial treatment of people with metastatic non-small cell lung ...
Tags: FDA, Tarceva Tablets, Astellas Pharma
-
Molecular Response Introduced TargetX Platform for The Rapid Discovery
Apr 11, 2013Molecular Response has introduced TargetX platform for the rapid discovery and validation of new oncology targets. The integrated platform, which features 144,000 living tumor specimens, genomic databases and patient derived tumor models, ...
Tags: TargetX platform, oncology targets
-
The USFDA Has Accepted for Filing Astellas Pharma's Supplemental New Drug Application
Jan 18, 2013The USFDA has accepted for filing Astellas Pharma's supplemental new drug application (sNDA) for Tarceva (erlotinib) tablets for a genetically distinct form of advanced lung cancer. Astellas is seeking approval to use Tarceva as the ...
-
Astellas Pharma US Is Seeking FDA Approval
Dec 14, 2012Astellas Pharma US is seeking FDA approval for Tarceva tablets to treat non-small cell lung cancer patients (NSCLC) with tumors containing epidermal growth factor receptor (EGFR) that triggers mutations. The company submitted a ...
-
European Commission Granted Conditional Marketing Authorization for Pfizer's Xalkori
Dec 6, 2012The European Commission has granted conditional marketing authorization for Pfizer’s Xalkori (crizotinib) to treat anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) in the European Union (EU). ...
Tags: Xalkori, crizotinib, anaplastic lymphoma kinase, ALK
-
Cytocell Unveiled a ROS1 Breakapart FISH Probe Test for Non-Small-Cell Lung Cancer
Dec 5, 2012Cytocell, a developer of fluorescence in situ hybridization (FISH) probes for use in cancer analysis, has unveiled a ROS1 Breakapart FISH probe test for non-small-cell lung cancer (NSCLC). The molecular cytogenetic test, which utilizes ...
-
Pfizer Has Received Positive Opinion From The Committee
Dec 4, 2012Pfizer has received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for crizotinib to treat adults with previously treated anaplastic lymphoma kinase (ALK)-positive ...
Tags: Pfizer, CHMP, anaplastic lymphoma kinase
